Alkermes PLC Reports Mixed Q1 2025 Results Amid Financial Challenges and Strategic Advances
Alkermes PLC reported mixed Q1 2025 financial results, with revenue exceeding expectations but earnings decreasing, as the company advances its Orexin 2 program and addresses complex health issues like Alcohol Use Disorder.
3 minutes to read